Linden Thomas Advisory Services’s Denali Therapeutics DNLI Stock Holding History

Linden Thomas Advisory Services’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-19,597	Closed	-$578K	–	396
2023 Q2	$578K	Buy	19,597 +372	+2%	+$10.5K	0.13%	289
2023 Q1	$443K	Buy	19,225 +961	+5%	+$26.4K	0.11%	301
2022 Q4	$508K	Buy	+18,264	New	+$543K	0.14%	247

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Linden Thomas Advisory Services's DNLI Position: Q3 2023 in Review

Linden Thomas Advisory Services sold out of Denali Therapeutics (DNLI) in Q3 2023, closing a stake of 19,597 shares — an estimated $578K sold.

Linden Thomas Advisory Services first reported a position in DNLI in Q4 2022 and held it in 3 quarters. The position peaked at $578K in Q2 2023. 194 funds tracked by Wall St. Rank hold DNLI as of Q3 2023.

Linden Thomas Advisory Services reported no remaining Denali Therapeutics position as of Q3 2023 after selling out during the quarter.
Linden Thomas Advisory Services sold 19,597 Denali Therapeutics shares in Q3 2023, an estimated $578K.
Linden Thomas Advisory Services first reported a position in Denali Therapeutics in Q4 2022 and held it in 3 quarters.
Linden Thomas Advisory Services's Denali Therapeutics position peaked at $578K in Q2 2023.
194 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2023.

Based on Linden Thomas Advisory Services's 13F filing for Q3 2023, filed 20 Oct 2023.